p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 2. Improved Renal Function as Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 3, 2003, Pages 939-946

  Lenhard, Stephen C ^a   Nerurkar, Sandhya S ^a   Schaeffer, Thomas R ^a   Mirabile, Rosanna C ^a   Boyce, Rogely W ^a   Adams, David F ^a   Jucker, Beat M ^a   Willette, Robert N ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 HYDROXYCYCLOHEXYL) 4 (4 FLUOROPHENYLMETHOXYPYRIMIDIN 4 YL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; GADOLINIUM PENTETATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CREATININE URINE LEVEL; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HISTOLOGY; HYPERTENSION; KIDNEY FUNCTION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TARGET ORGAN;

ALBUMINURIA; ANIMALS; CEREBROVASCULAR ACCIDENT; CONTRAST MEDIA; CREATININE; DIETARY FATS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GADOLINIUM DTPA; GLOMERULAR FILTRATION RATE; HYPERTENSION; IMIDAZOLES; KIDNEY; KIDNEY FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIMIDINES; RATS; RATS, INBRED SHR; SODIUM, DIETARY;

EID: 0345550539     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.057398     Document Type: Article

References (21)

1. Aumann S, Schoenberg S, Just A, Briley-Saebo K, Bjornerud A, Bock M, and Brix G (2003) Quantification of renal perfusion using an intravascular contrast agent (Part 1): results in a canine model. Magn Res Med 49:276-287.
2. Barone F, Irving E, Ray A, Lee J, Kassis S, Kumar S, Badger A, Legos J, Erhardt J, Ohlstein E, et al. (2001) Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med Res Rev 21:129-145.
3. Baumann D and Rudin M (2000) Quantitative assessment of rat kidney function by measuring the clearance of the contrast agent Gd(DOTA) using dynamic MRI. Magn Res Imaging 18:587-595.
4. Behr T, Nerurkar S, Nelson A, Coatney R, Woods T, Sulpizio A, Chandra S, Brooks D, Kumar S, Lee J, et al. (2001) Hypertensive end organ damage and premature mortality are p38 mitogen-activated protein kinase dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104:1292-1298.
5. Bennet H and Li D (1997) MR Imaging of Renal Function. MRI Clin N Am 5:107-126.
6. Chen S and Gardiner D (2002) Osmoregulation of natriuretic peptide receptor signaling in inner medullary collecting duct. A requirement for p38 MAPK. J Biol Chem 277:6037-6043.
7. Darling I and Morris M (1991) Evaluation of "true" creatinine clearance in rats reveals extensive renal secretion. Pharm Res (NY) 10:1318-1322.
8. Evans J, Goldfine I, Maddux B, and Grodsky G (2002) Oxidative stress and stress activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocrin Rev 5:599-622.
9. Furuichi K, Wada T, Iwata Y, Sakai N, Yoshimoto K, Kobayashi K, Mukaida N, Matsushima K, and Yokoyama H (2002) Administration of FR-167653, a new anti-inflammatory compound, prevents renal ischaemia/reperfusion injury in mice. Nephrol Dial Transplant 17:399-407.
10. Herlaar E and Brown Z (1999) p38 MAPK signaling cascades in inflammatory disease. Mol Med Today 5:439-447.
11. Ju H, Behm DJ, Nerurkar S, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA, and Willette RN (2003) p38 Mitogen-activated protein kinase (MAPK) inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther 307:931-937.
12. Laurent D, Poirer K, Wasvary J, and Rudin M (2001) Effect of essential hypertension on kidney function as measured in rat by dynamic MRI. Magn Res Med 47:127-134.
13. Li H and Nord E (2002) CD40 ligation stimulates MCP-1 and IL-8 production, TRAF6 recruitment and MAPK activation in proximal tubule cells. Am J Physiol 6:F1020-F1033.
14. Li W, Nadelman C, Henry G, Fan J, Muellenhoff M, Medina E, Gratch N, Chen M, Han J, and Woodley D (2001) The p38-MAPK/SAPK Pathway is required for human keratinocyte migration on dermal collagen. J Investig Dermatol 117:1601-1611.
15. Park K, Chen A, and Bonventre J (2001) Prevention of Kidney Ischemia/reperfusion-induced functional injury and JNK, p38 and MAPK kinase activation by remote ischemic pretreatment. J Biol Chem 276:11870-11876.
16. Reddy M, Adler S, Kim Y, Lanting L, Rossi J, Nadler J, Shahed A, and Natarajan R (2002) Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol 5:F985-F994.
17. Tian W, Zhang Z, and Cohen D (2000) MAPK signaling and the kidney. Am J Physiol 279:F593-F604.
18. Tomlinson D (1999) Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 42:1271-1281.
19. Vallee JP, Lazeyras F, Khan HG, and Terrier F (2000) Absolute renal blood flow quantification by dynamic MRI and Gd-DTPA. Eur Radiol 10:1245-1252.
20. Wada T, Furuichi K, Sakai N, Hisada Y, Kobayashi K, Mukaida N, Tomosugi N, Matsushima K, and Yokoyama H (2001) Involvement of p38 mitogen-activated protein kinase followed by chemokine expression in crescentic glomerulonephritis. Am J Kid Dis 38:1169-1177.
21. Ying W and Sanders P (2002) Dietary salt intake activates MAP kinases in the rat kidney. FASEB J 16:1683-1684.